

Petri Bono

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9078422/publications.pdf>

Version: 2024-02-01

68
papers

4,257
citations

257450

24
h-index

118850

62
g-index

69
all docs

69
docs citations

69
times ranked

6702
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 883-895.	10.7	1,091
2	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1590-1598.	10.7	594
3	Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1412-1418.	1.6	381
4	Initial efficacy of anti-lymphocyte activation gene-3 (anti-“LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-“PD-1/PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9520-9520.	1.6	188
5	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	1.6	185
6	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 244-250.	1.6	174
7	Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. <i>Lancet Oncology</i> , The, 2014, 15, 975-985.	10.7	172
8	High LYVE-1-“Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7144-7149.	7.0	156
9	Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 11-18.	1.6	114
10	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1700-1710.	10.7	108
11	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2019, 108, 33-40.	2.8	96
12	Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 793.	7.1	74
13	Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. <i>Lancet Oncology</i> , The, 2009, 10, 1145-1151.	10.7	65
14	Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. <i>Acta Oncologica</i> , 2011, 50, 569-573.	1.8	63
15	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1730-1736.	6.4	63
16	Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. <i>Cancer</i> , 2003, 97, 2767-2775.	4.1	52
17	CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4010-4010.	1.6	50
18	Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. <i>European Urology</i> , 2016, 69, 834-840.	1.9	49

#	ARTICLE	IF	CITATIONS
19	Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. <i>BJU International</i> , 2016, 117, 110-117.	2.5	47
20	Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. <i>Breast</i> , 2015, 24, 182-190.	2.2	44
21	Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4501-4501.	1.6	36
22	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6-6.	1.6	33
23	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. <i>European Urology Focus</i> , 2018, 4, 547-553.	3.1	30
24	Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4205-4220.	7.0	29
25	Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)â€”PISCES study, NCT 01064310.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA4502-CRA4502.	1.6	27
26	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. <i>Modern Pathology</i> , 2021, 34, 2229-2241.	5.5	25
27	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	3.7	22
28	CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 498-498.	1.6	21
29	Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0153745.	2.5	20
30	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. <i>European Urology Focus</i> , 2017, 3, 606-614.	3.1	18
31	Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)â€”PISCES study, NCT 01064310.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA4502-CRA4502.	1.6	18
32	Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 487-494.	1.9	16
33	Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 384-390.e3.	1.9	14
34	Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102054.	1.6	14
35	VEGFR3 and CD31 as prognostic factors in renal cell cancer. <i>Anticancer Research</i> , 2015, 35, 921-7.	1.1	13
36	Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 380-386.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Cancer costs and outcomes in the Finnish population 2004–2014. <i>Acta Oncologica</i> , 2018, 57, 297-303.	1.8	10
38	Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 507-507.	1.6	10
39	Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3114-TPS3114.	1.6	10
40	Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-414.	1.6	10
41	Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e283-e289.	1.9	9
42	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e526-e533.	1.9	9
43	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 406-414.	1.9	8
44	p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. <i>Clinical Cancer Research</i> , 2018, 24, 3046-3052.	7.0	8
45	Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 10505-10505.	1.6	8
46	ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 63-70.	3.1	7
47	Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Cells</i> , 2022, 11, 17.	4.1	7
48	Cancer costs and outcomes for common cancer sites in the Finnish population between 2009–2014. <i>Acta Oncologica</i> , 2018, 57, 983-988.	1.8	6
49	Modularising outpatient care delivery: A mixed methods case study at a Finnish University Hospital. <i>Health Services Management Research</i> , 2018, 31, 195-204.	1.7	6
50	Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. <i>ESMO Open</i> , 2020, 5, e001081.	4.5	6
51	Novel Angiogenesis Markers as Long-Term Prognostic Factors in Patients With Renal Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e15-e24.	1.9	5
52	ODM-201 and the CNS: A clinical perspective. <i>Journal of Clinical Oncology</i> , 2014, 32, 275-275.	1.6	4
53	A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC). <i>Journal of Clinical Oncology</i> , 2014, 32, 115-115.	1.6	3
54	Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1001-1001.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours.. Journal of Clinical Oncology, 2016, 34, 2576-2576.	1.6	3
56	A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. OncoTargets and Therapy, 2014, 7, 1177.	2.0	2
57	Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.. Journal of Clinical Oncology, 2015, 33, 230-230.	1.6	2
58	Promising clinical benefit rates in advanced cancers alongside potential biomarker correlation in a phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy.. Journal of Clinical Oncology, 2022, 40, 2645-2645.	1.6	2
59	Helicobacter pylori and gastrointestinal symptoms in diagnostics and adjuvant chemotherapy of colorectal cancer. Oncology Letters, 2014, 7, 553-559.	1.8	1
60	Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.. Journal of Clinical Oncology, 2014, 32, 5079-5079.	1.6	1
61	A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.. Journal of Clinical Oncology, 2013, 31, TPS4592-TPS4592.	1.6	1
62	Reply to M. Isik et al. Journal of Clinical Oncology, 2010, 28, e335-e336.	1.6	0
63	Principal: A prospective observational study of real-world treatment patterns and treatment outcomes in patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib.. Journal of Clinical Oncology, 2014, 32, TPS4600-TPS4600.	1.6	0
64	Correlation of endothelial angiotensin-2 expression with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 461-461.	1.6	0
65	ODM-204 a novel dual inhibitor of CYP17A1 and androgen receptor: Early results from phase I dose escalation in men with castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, 246-246.	1.6	0
66	Prospective, multinational, observational study of real-world treatment outcomes with pazopanib in patients with advanced or metastatic renal cell carcinoma (PRINCIPAL study).. Journal of Clinical Oncology, 2018, 36, 4574-4574.	1.6	0
67	Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 4561-4561.	1.6	0
68	Modelling treatment benefit for bexmarilimab (an anti-Clever-1 antibody and a novel macrophage) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 e14500-e14500.	1.6	0